Daniel Long Sells 3,333 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,333 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $34.36, for a total value of $114,521.88. Following the transaction, the senior vice president owned 96,412 shares of the company’s stock, valued at $3,312,716.32. This trade represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Septerna Stock Down 1.8%

NASDAQ SEPN traded down $0.61 during trading on Thursday, hitting $34.00. The stock had a trading volume of 475,806 shares, compared to its average volume of 340,206. The company has a market capitalization of $1.53 billion, a PE ratio of -41.97 and a beta of 2.28. The firm has a 50 day moving average price of $29.73 and a 200 day moving average price of $27.55. Septerna, Inc. has a twelve month low of $10.62 and a twelve month high of $37.99.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.23. The business had revenue of $26.52 million for the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. On average, sell-side analysts anticipate that Septerna, Inc. will post -1.59 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SEPN. Avoro Capital Advisors LLC raised its position in shares of Septerna by 8.1% during the 3rd quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock worth $25,158,000 after acquiring an additional 100,000 shares in the last quarter. First Light Asset Management LLC boosted its holdings in Septerna by 18.0% in the first quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock valued at $17,611,000 after purchasing an additional 112,049 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Septerna in the first quarter valued at approximately $906,000. Swiss National Bank purchased a new position in Septerna in the first quarter valued at approximately $531,000. Finally, Bank of New York Mellon Corp raised its holdings in Septerna by 6.1% during the first quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock worth $1,411,000 after purchasing an additional 3,377 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have commented on SEPN. Cantor Fitzgerald reissued an “overweight” rating and issued a $60.00 price target on shares of Septerna in a research report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Septerna in a report on Wednesday. Truist Financial boosted their target price on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Stifel Nicolaus assumed coverage on Septerna in a report on Friday, May 1st. They set a “buy” rating and a $43.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.89.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.